AzTrials
AzTrials

Ischemic Heart DiseaseBHC-CNCT05961748

Registry of Multicenter Brain-Heart Comorbidity in China

An observational study of Ischemic Heart Disease and Cardiac Arrest, run by Beijing Tiantan Hospital at 14 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study is a multi-center, prospective, registry study. This research was supported by the National Key Research and Development Program. To establish a domestic multi-center, large-scale "brain-heart comorbidity" dynamic database platform including clinical, sample database, image and other multi-dimensional… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Multi-disciplinary assessment
How many people
100,000 participants
Where
14 sitesChina
Study dates
1 Jan 2012to 31 Dec 2032
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Inclusion Criteria: * age > 18 years old * Any of newly diagnosed cardiovascular-related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) [i.e., ACS], I46 (cardiac arrest), I48 (Atrial fibrillation/flutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels). Exclusion Criteria: ·refuse to participate in the registry

Who may be able to join

  • age > 18 years old
  • Any of newly diagnosed cardiovascular-related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) [i.e., ACS], I46 (cardiac arrest), I48 (Atrial fibrillation/flutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).

Who cannot join

  • ·refuse to participate in the registry

Trial locations and contacts

14 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Xiaolin Chen, MD contact

13810624845

cxl_bjtth@163.com

Fa Lin, MD contact

13681107240

13681107240@163.com

14 sites in 1 country

China14 sites, 14 recruiting

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100070

    Fa Lin, MD, 13681107240, 13681107240@163.com

    Recruiting

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality

    Ming Gong, MD

    Hai Gao, MD

    Not yet recruiting

  • Beijing Chaoyang Hospital, Capital Medical University

    Beijing, Beijing Municipality

    Xiaojuan Guo, MD

    Not yet recruiting

  • Chinese People's Liberation Army (PLA) General Hospital

    Beijing, Beijing Municipality

    Hang Zhu, MD

    Not yet recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality

    Wei Ma, MD

    Xinggang Wang, MD

    Not yet recruiting

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing Municipality

    Yingqi Xing, MD

    Not yet recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian

    Dezhi Kang, MD

    Not yet recruiting

  • The First Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang

    Huaizhang Shi, MD

    Not yet recruiting

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan

    Jun Pu, MD

    Not yet recruiting

  • Huashan Hospital of Fudan University

    Shanghai, Shanghai Municipality

    Bin Xu, MD

    Feng Xu, MD

    Not yet recruiting

  • Shanxi Provincial People's Hospital

    Shanxi, Shanxi

    Shaohua Ren, MD

    Not yet recruiting

  • Shenzhen Qianhai Shekou Free Trade Zone Hospital

    Shenzhen, Guangdong

    Zhiwei Wang, MD

    Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian

    Sifang Chen, MD

    Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan

    Dongming Yan, MD

    Guosheng Zhou, MD

    Not yet recruiting

Other trials in China

About this study

This study is a multi-center, prospective, registry study. This research was supported by the National Key Research and Development Program. To establish a domestic multi-center, large-scale "brain-heart comorbidity" dynamic database platform including clinical, sample database, image and other multi-dimensional information requirements, through the construction of a multi-center intelligent scientific research integration platform based on artificial intelligence.

Any of newly diagnosed cardiovascular related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) [i.e., ACS], I46 (cardiac arrest), I48 (Atrial fibrillation/flutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).

The data is stored on the brain-heart comorbidity warehouse via a physical server at the institution's data centre or a virtual hosted appliance. The brain-heart comorbidity platform comprises of a series of these appliances connected into a multicenter network. This network can broadcast queries to each appliance. Results are subsequently collected and aggregated. Once the data is sent to the network, it is mapped to a standard and controlled set of clinical terminologies and undergoes a data quality assessment including 'data cleaning' that rejects records which do not meet the brain-heart comorbidity quality standards. The brain-heart comorbidity warehouse performs internal and extensive data quality assessment with every refresh based on conformance, completeness, and plausibility (http://10.100.101.65:30080/login).

Being tested
Multi-disciplinary assessment
Medical subject headings
Myocardial Ischemia, Heart Arrest, Atrial Fibrillation, Heart Failure, Aortic Diseases, Subarachnoid Hemorrhage, Cerebral Hemorrhage, Cerebral Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multi-disciplinary assessmentOther

    Multi-disciplinary assessment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of Participants with Composite of All-Cause Mortality and Cardiovascular Outcomes

    The occurrence of all-cause mortality, coronary artery disease event, stroke (ischemic or hemorrhagic), heart failure, or atrial fibrillation etc.

    Measured: At discharge/30 days

  2. All-Cause Mortality

    The occurrence of death

    Measured: At discharge/30 days

  3. Rate of Participants with Composite of Cardiovascular Outcomes

    The occurrence of coronary artery disease event, stroke (ischemic or hemorrhagic), heart failure, or atrial fibrillation etc.

    Measured: At discharge/30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jul 2023
  2. Study start1 Jan 2012
  3. Primary completion31 Dec 2032 (estimated)
  4. Study completion31 Dec 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05961748
Sponsor's protocol ID
KY2022-221-02
Acronym
BHC-C
Status last verified
Sep 2023
First submitted
7 Jul 2023
Last updated
21 Sep 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Lu J, Lin F, Weng J, Lyu J, Zhang L, Song W, Zhu B, Ma M, Xu H, Xue J, Liu M, Zhang Y, Chen Y, Li R, Wang K, Liu H, Chen X, Zhao J, Liu MJ. Serum Lipid Profiles and the Burden of Polyvascular Atherosclerosis: A Cross-Sectional CTA-Based Study in a Chinese Cohort. J Stroke Cerebrovasc Dis. 2026 Jul 30:108715. doi: 10.1016/j.jstrokecerebrovasdis.2026.108715. Online ahead of print.

    PubMed 42532457

Questions about this trial

What is this clinical trial studying?

An observational study of Ischemic Heart Disease and Cardiac Arrest, run by Beijing Tiantan Hospital at 14 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 14 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Xiaolin Chen, MD (13810624845, cxl_bjtth@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of Participants with Composite of All-Cause Mortality and Cardiovascular Outcomes (time frame: At discharge/30 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05961748, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in